Cost-Effectiveness Analysis of Quadripolar Versus Bipolar Left Ventricular Leads for Cardiac Resynchronization Defibrillator Therapy in a Large, Multicenter UK Registry  by Behar, Jonathan M. et al.
J A C C : C L I N I C A L E L E C T R O P H Y S I O L O G Y VO L . - , N O . - , 2 0 1 6
ª 2 0 1 6 T H E A U T H O R S . P U B L I S H E D B Y E L S E V I E R O N B E H A L F O F T H E A M E R I C A N
C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R
T H E C C B Y - N C - N D L I C E N S E ( h t t p : / / c r e a t i v e c o mm o n s . o r g / l i c e n s e s / b y - n c - n d / 4 . 0 / ) .
I S S N 2 4 0 5 - 5 0 0 X
h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c e p . 2 0 1 6 . 0 4 . 0 0 9Cost-Effectiveness Analysis of
Quadripolar Versus Bipolar Left Ventricular
Leads for Cardiac Resynchronization
Deﬁbrillator Therapy in a Large,
Multicenter UK Registry
Jonathan M. Behar, MBBS, BSC,a,b Hui Men Selina Chin, BA,b Steve Fearn, PHD,c Julian O.M. Ormerod, MBBS,d
James Gamble, MBBS,d Paul W.X. Foley, MD,e Julian Bostock, PHD,a,b Simon Claridge, MBBS, LLB,a,b
Tom Jackson, MBBS,a,b Manav Sohal, MBBS,a,b Antonios P. Antoniadis, MD, PHD,a,b Reza Razavi, MD,a
Tim R. Betts, MD,d Neil Herring, DPHIL,d Christopher Aldo Rinaldi, MDa,bABSTRACTFro
dio
Kin
Kin
fro
Tru
an
He
edOBJECTIVES The objective of this study was to evaluate the cost-effectiveness of quadripolar versus bipolar cardiac
resynchronization deﬁbrillator therapy systems.
BACKGROUND Quadripolar left ventricular (LV) leads for cardiac resynchronization therapy reduce phrenic nerve
stimulation (PNS) and are associated with reduced mortality compared with bipolar leads.
METHODS A total of 606 patients received implants at 3 UK centers (319 Q, 287 B), between 2009 and 2014; mean
follow-up was 879 days. Rehospitalization episodes were costed at National Health Service national tariff rates, and EQ-
5D utility values were applied to heart failure admissions, acute coronary syndrome events, and mortality data, which
were used to estimate quality-adjusted life-year differences over 5 years.
RESULTS Groups were matched with regard to age and sex. Patients with quadripolar implants had a lower rate of
hospitalization than those with bipolar implants (42.6% vs. 55.4%; p ¼ 0.002). This was primarily driven by fewer
hospital readmissions for heart failure (51 [16%] vs. 75 [26.1%], respectively, for quadripolar vs. bipolar implants; p ¼
0.003) and generator replacements (9 [2.8%] vs. 19 [6.6%], respectively; p ¼ 0.03). Hospitalization for suspected acute
coronary syndrome, arrhythmia, device explantation, and lead revisions were similar. This lower health-care utilization
cost translated into a cumulative 5-year cost saving for patients with quadripolar systems where the acquisition cost
was <£932 (US $1,398) compared with bipolar systems. Probabilistic sensitivity analysis results mirrored the deter-
ministic calculations. For the average additional price of £1,200 (US $1,800) over a bipolar system, the incremental cost-
effective ratio was £3,692 per quality-adjusted life-year gained ($5,538), far below the usual willingness-to-pay
threshold of £20,000 (US $30,000).
CONCLUSIONS In a UK health-care 5-year time horizon, the additional purchase price of quadripolar cardiac
resynchronization deﬁbrillator therapy systems is largely offset by lower subsequent event costs up to 5 years after
implantation, which makes this technology highly cost-effective compared with bipolar systems. (J Am Coll Cardiol EP
2016;-:-–-) © 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
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2C ardiac resynchronization therapy(CRT) is an efﬁcacious and cost-effective (1) treatment for patients
with symptomatic heart failure with poor
left ventricular (LV) function and prolonged
QRS duration (2–4). Despite improvements
in implantation delivery equipment and
accumulation of user experience over the
past 2 decades, approximately 30% of pa-
tients do not derive symptomatic beneﬁt
(5,6). Post-implantation complications such
as high capture thresholds, phrenic nerve
stimulation (PNS), lead displacement, and
infection reduce the effectiveness of this
therapy (7–10). The recent introduction of
multipolar (quadripolar) LV leads has
demonstrated a reduction in PNS through
more proximal pole reprogramming, the
presence of sustained lower capture thresh-
olds, and easy deliverability (11).However, new technology is usually provided at a
higher purchase price than the conventional standard
of care, which means that cost-effectiveness and
affordability must be considered (12). Furthermore,
the need for £22 billion in savings by 2020 in the
United Kingdom (13) and an increased focus on efﬁ-
ciency as a result (14) further highlight the impor-
tance of cost-effective care. Multiple small clinical
studies have demonstrated the clinical effectiveness
of quadripolar leads at implantation and early follow-
up (8,15). Implant and 6-month follow-up data
recently presented from the randomized MORE-CRT
(More Options Available With a Quadripolar LV Lead
Provide In-Clinic Solutions to CRT Challenges) trial
(16) have conﬁrmed the superiority of quadripolar
leads, mainly from a reduction in intraoperative
complications. We have previously demonstrated
elimination of PNS and an associated lower all-cause
mortality in patients implanted with a quadripolar
lead in a large multicenter UK registry (17) (Online
Figure 1).
We set out to assess the cost-effectiveness of
quadripolar LV leads compared with bipolar LV leads
in patients implanted with a cardiac resynchroniza-
tion deﬁbrillator therapy device (CRTD) within our
previously published registry. We analyzed longer-nt and speaker fees from Boston Scientiﬁc Ltd. and Medtronic Ltd
erring is a British Heart Foundation (BHF) Intermediate Fellow;
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received September 29, 2015; revised manuscript received Aprilterm health-care utilization costs in terms of hospi-
talizations that occurred within the 5-year follow-up
period to investigate whether the higher purchase
price of this new technology was offset by expected
reductions in cost arising from a reduction in hospi-
talizations. We also used mortality, acute coronary
syndrome, and heart failure hospitalization data
to estimate quality-adjusted life-year (QALY)
differences.
METHODS
Clinical data were taken from a registry of patients
with conventional CRT criteria who received device
implants at 3 UK centers (Guy’s and St Thomas’ NHS
Foundation Trust; John Radcliffe Hospital, Oxford
University Hospital NHS Foundation Trust; and Great
Western Hospital, Swindon) between January 2009
and January 2014. All patients provided fully
informed consent. We have previously published the
results of 5-year follow-up of patients, in which we
compared patients with CRTD systems with a quad-
ripolar versus a bipolar LV lead in terms of PNS, lead
complications, and all-cause mortality (17).
For the purposes of the current study, hospitali-
zation episodes for each patient in the clinical registry
were reviewed and assigned to the following cate-
gories based on diagnosis: acute coronary syndrome
(ACS), arrhythmia, heart failure hospitalizations,
infection requiring system explantation and reim-
plantation, generator replacement, and revision of
any lead. These were compared between patients
implanted with a CRTD incorporating a quadripolar
LV lead versus those with a bipolar LV lead.
Quadripolar leads in the current analysis were
exclusively the Quartet lead (St. Jude Medical,
Sylmar, California). Only individuals with complete
hospitalization data that included coding of the cause
of hospitalization were included; as such, the cohort
comprised 606 patients (quadripolar, n ¼ 319; bipolar,
n ¼ 287).
We performed an economic analysis of the registry
data using all hospitalizations that occurred during
the follow-up period. The rates of hospitalizations in
each year from implantation were multiplied by the
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TABLE 1 National Tariff Tables: Hospitalization Pricing by Coding Category
Cost Item Value (£) Description Source (Ref. #)
ACS hospitalization 3,421 EB10Z (actual or suspected MI),
nonelective
ETO 2015–2016 (18)
Arrhythmia
hospitalization
887 Activity-weighted average of
EB07H (arrhythmia or
conduction disorders with CC)
and EB07I (arrhythmia or
conduction disorders
without CC)
ETO 2015–2016 (18)
Heart failure
admission
2,756 Activity-weighted average of
EB03H (heart failure or shock
with CC) and EB03I (heart
failure or shock without CC)
ETO 2015–2016 (18)
Lead revision
procedure
2,952 Activity-weighted average of
elective/nonelective HRG
EA39Z (pacemaker procedure
without generator implant;
includes removal and
reimplantation of cardiac
pacemaker system)
ETO 2015–2016 (18)
Bipolar CRTD
device
12,615 NICE technology
appraisal (19)
Additional cost of
quadripolar
CRTD device
1,200 Base-case value, varied between
£0 and £2,400 in sensitivity
analysis
Market estimate
2015
Device removal and
reimplantation for
infection
23,506 Base value for bipolar
device
NICE technology
appraisal 2014 (19)
CRTD generator
revision
15,990 Base value for bipolar
device
NICE technology
appraisal 2014 (19)
See Online Figure 1 for equivalent cost in US dollars.
ACS ¼ acute coronary syndrome; CC ¼ complications and comorbidities; CRTD ¼ cardiac resynchronization
deﬁbrillator therapy device; ETO ¼ extended tariff option (the national tariff scheme used by most English trusts
in 2015–2016); MI ¼ myocardial infarction; NICE ¼ National Institute for Health and Care Excellence.
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3hospitalization (Table 1). There was no extrapolation
of data or event rates beyond the 5-year follow-up
after implantation. Event rates were those that were
observed to have occurred in each year; we did not
derive transition probabilities that could be used for a
Markov model. All events were counted, and some
events occurred more than once in individual pa-
tients. A probabilistic sensitivity analysis was also
undertaken to help understand the impact of
parameter uncertainty and determine the probability
that quadripolar CRTD was cost-effective. Probabi-
listic analysis was conducted by inputting data as
probability (beta) distributions rather than point es-
timates and randomly sampling 1,000 values from
these distributions. This was performed for all hos-
pitalization episodes in addition to mortality data
from our previous work (17). Comparative purchase
costs were estimated between the quadripolar Quar-
tet leads (St. Jude Medical) and the mean purchase
cost of bipolar leads used in the clinical registry
(QuickFlex, St. Jude Medical; AttainAbility, Med-
tronic; Easytrak, Boston Scientiﬁc). A National Health
Service (NHS, the UK health system) perspective was
used, which means that wider societal impact was not
considered. Costs and effects beyond year 1 were
discounted at 3.5%, following the methodology rec-
ommended by the UK’s National Institute of Health
and Care Excellence (NICE) (20). A model diagram
(Figure 1) demonstrates the differing probabilities of
hospitalization event rates (per cause) for year 1 post-
implantation in those with quadripolar and bipolar
systems. The same approach was used for years 2 to 5
in the analysis, and rates for all years are shown in
Online Table 1.
COSTS. National tariff “enhanced tariff option” pri-
ces for 2015 to 2016 (18) were applied to ACS hospi-
talization, arrhythmia hospitalization, heart failure
hospitalization, and lead revision procedures. The
base tariff price was multiplied by the local cost factor
(market forces factor) for each NHS hospital that im-
plants CRT devices, and the mean of these values was
used in the model. Table 1 shows the mean unit cost
data used in the calculations per hospitalization,
including local cost factors. Online Table 2 shows the
equivalent costs in US dollars using a simple conver-
sion of £1 ¼ $1.50. Where there were different tariff
values for elective/nonelective procedures and
different values for complication/comorbidity splits,
averages weighted by the number of admissions for
each were calculated. Costs for CRTD implantation,
device removal and reimplantation for wound infec-
tion, and CRT generator replacement were taken from
the data used to inform the economic evaluation that
underpinned NICE’s 2014 Technology AppraisalGuidance (19). The additional purchase cost of quad-
ripolar technology was estimated to be £1,200
($1,800) for the base-case analysis (market estimate,
St. Jude Medical) but varied between zero and £2,400
($3,600) to assess sensitivity, because acquisition
price may vary according to local procurement ar-
rangements. Quadripolar device removal and reim-
plantation for infection was uplifted by the additional
acquisition cost for the quadripolar device, on the
assumption that the same type of device would be
reimplanted. Quadripolar generator replacement was
costed at bipolar cost plus 0.67 of additional quad-
ripolar system costs. Quadripolar lead revision was
costed at bipolar cost plus 0.33 of additional quad-
ripolar system costs.
QUALITY-ADJUSTED LIFE YEARS. The use of QALYs
allows clinical effectiveness to be expressed in a
common unit, to which a cost can be applied to esti-
mate the value of health-care interventions. The EQ-
5D questionnaire is commonly used to determine
the quality-of-life utility values that can be translated
into QALYs (21). Hawkins et al. (22) discussed this
approach in the context of cardiac interventions, and
it is a standard part of NICE’s methodology (20).
FIGURE 1 Model Diagram and Decision Structure Used in the Economic Model
Quadripolar
Bipolar
Y1 p = 0.025
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Y1 p = 0.097
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Y1 p = 0.049
Y1 p = 0.021
Y1 p = 0.098
Y1 p = 0.087
Y1 p = 0.101
Y1 p = 0.012
Y1 p = 0.003
Requirement for CRT-D
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This was used for each of the 5 years, although only year 1 is shown here. Y1 p is the probability of the event in year 1; actual data for year 1 are
shown. ACS ¼ acute coronary syndrome; CRT-D ¼ cardiac resynchronization deﬁbrillator therapy device.
Behar et al. J A C C : C L I N I C A L E L E C T R O P H Y S I O L O G Y V O L . - , N O . - , 2 0 1 6
Cost-Effectiveness of Quadripolar vs. Bipolar CRTD - , 2 0 1 6 :- –-
4The incremental cost-effectiveness ratio (ICER) is
obtained by dividing the additional cost of using the
new device by the incremental QALYs gained and can
be used to estimate a value for decision-making
purposes. NICE’s methods guide (20) suggests an
ICER of £20,000 ($30,000) to £30,000 ($45,000) is the
range in which cost-effectiveness is acceptable in
terms of effective use of NHS resources; therefore,
this was the benchmark used to assess the results of
the current study.
Only the mortality difference used in our previous
report (17), utility loss attributable to ACS events, and
utility loss attributable to heart failure hospitaliza-
tions were used to assess QALY differences between
bipolar and quadripolar devices, similar to the
methods used in the economic analysis that informed
NICE’s recent technology appraisal of implantable
cardioverter-deﬁbrillators and CRT (19). A baseline
EQ-5D utility of 0.8808 was used for a patient with
heart failure and a CRT device (range: 0.85 to 0.903),
with utility loss because of death being taken as a loss
from this value to zero. The utility loss associated
with a heart failure admission was calculated, fromthe work of Swinburn et al. (23) and Lewis et al. (24),
to be 0.1197, persisting for 18 days (average length of
stay plus 7 days post-discharge). The utility loss
associated with ACS events was calculated, from the
work of Lewis et al. (24) and Matza et al. (25), to be
0.1035, persisting for 10.4 days (average length of
stay plus 7 days post-discharge). A range of input
parameters were varied by  95% conﬁdence interval
to show the impact of each on the base-case ICER,
and the results are shown on a tornado plot
(Figure 2).
STATISTICAL ANALYSIS. Continuous variables are
expressed as mean  SD. Comparisons were made
with a Student t test. Categorical data were expressed
as an absolute number of occurrences and associated
frequency (%); analysis was performed with a chi-
squared test. A probability value of <0.05 was
considered signiﬁcant. Statistical analysis was per-
formed with the Statistics Package for the Social Sci-
ences (SPSS) version 21 (SPSS Inc., Chicago, Illinois).
Economic analysis was undertaken in Microsoft
Excel.
FIGURE 2 Tornado Plot Showing the Impact of Varying the Input Parameter Values to Their Upper and Lower 95% CIs on the
Base-Case ICER
£3,500
uHF with CRT
cWound intervenon
cLead revision
uloss HF hosp
cBox change
cACS hosp
cHF hosp
uloss ACS
cArrhythmia
£3,550 £3,600
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£3,770
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£3,682
£3,684
£3,687
£3,690
£3,691
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ICER (£ per QALY Gained)
Hatched bars show the impact of using the lower 95% conﬁdence interval (CI); solid bars show the impact of using the upper 95% CI. Data
labels on each bar show the incremental cost-effectiveness ratio (ICER) resulting from the change in value. A shift to the right of the center line
shows an ICER that denotes less favorable cost-effectiveness than the base case. ACS ¼ acute coronary syndrome; c ¼ cost of; HF ¼ heart
failure; hosp ¼ hospitalization; QALY ¼ quality-adjusted life-year; quad ¼ quadripolar cardiac resynchronization therapy system; u ¼ utility
value.
TABLE 2 Demographic Data
Quadripolar
(n ¼ 319)
Bipolar
(n ¼ 287) p Value
Age (yrs) 70.4  11 68.7  10 0.06
Female 50 (15.7) 48 (16.7) 0.74
Ischemic heart disease 181 (56.7) 190 (66.2) 0.02
Sinus rhythm 303 (95.0) 48 (83.3) <0.001
QRS duration (ms) 159  6.2
(n ¼ 238)
160  5.1
(n ¼ 201)
0.07
NYHA functional class III symptoms 183 (76.9)
(n ¼ 238)
145 (72.1)
(n ¼ 201)
0.10
Mobitz II/complete heart block 9 (2.8) 14 (4.9) 0.21
% Biventricular pacing 94.6  1.6 94.4  1.5 0.11
LV lead upgrade 8 (2.5) 61 (21.3) <0.001
Length of stay post-implantation
(days) (elective)
1.2  2.3 1.2  1.6 1.00
Length of stay post-implantation
(days) (inpatient)
5.0  8.5 5.2  7.2 0.76
Values are mean  SD or n (%).
LV ¼ left ventricular; NYHA ¼ New York Heart Association.
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5RESULTS
A total of 606 patients were included in this analysis
and were matched with regard to age and sex. Pa-
tients in the bipolar group had a higher prevalence of
ischemic heart disease (quadripolar vs. bipolar: 181
[56.7%] vs. 190 [66.2%]; p ¼ 0.02), and fewer were in
sinus rhythm (quadripolar vs. bipolar: 303 [95.0%] vs.
48 [83.3%]; p < 0.001) before implantation. Mean QRS
duration was similar between groups (159  6.2 ms vs.
160  5.1 ms, quadripolar vs. bipolar, respectively;
p ¼ 0.07), as was the proportion of patients in New
York Heart Association functional class III (183
[76.9%] vs. 145 [72.1%], quadripolar vs. bipolar,
respectively; p ¼ 0.10). Mean percentage of biven-
tricular pacing throughout the follow-up period was
similar between groups (Q: 94.6  1.6% vs. B: 94.4 
1.5%, p ¼ 0.11). Length of stay after implantation was
similar between groups, irrespective of whether they
were elective admissions (1.2  2.3 days vs. 1.2  1.6
days, quadripolar vs. bipolar, respectively; p ¼ 1.00)
or existing inpatients (5.0  8.5 days vs. 5.2  7.2
days, quadripolar vs. bipolar, respectively; p ¼ 0.76),
as shown in Table 2.
Patients implanted with a quadripolar lead had a
signiﬁcantly lower absolute number of all-cause
hospitalizations (quadripolar: 191 admissions among
309 patients; bipolar: 225 admissions among 287 pa-
tients; p < 0.001), as shown in Table 3. Moreover, the
proportion of patients hospitalized at least once was
also signiﬁcantly lower in those implanted with aquadripolar compared with a bipolar lead (42.6% vs.
55.4%, respectively; p ¼ 0.002), as shown in Table 4.
This was primarily driven by a signiﬁcantly lower
number of hospitalizations for heart failure (51
admissions among 309 patients with a quadripolar
device vs. 75 among 287 patients with a bipolar
device; p ¼ 0.003) and CRTD generator replacement
(9 admissions among 309 patients vs. 19 among 287
patients, respectively; p ¼ 0.03). Hospitalizations for
suspected ACS, arrhythmia, device explantation, and
TABLE 3 Absolute Numbers of Hospitalization, Split by Cause,
and Corresponding Health-Care Costsa
Quadripolar
(n ¼ 319)
Bipolar
(n ¼ 287)
p Valuen Cost (£) n Cost (£)
ACS 35 115,029 21 67,544 0.13
Arrhythmia 59 51,218 65 55,557 0.23
Heart failure 51 137,695 75 195,841 0.003
System explantation
and reimplantation
5 121,122 6 136,788 0.76
Generator replacement 9 142,026 19 273,276 0.03
RA/RV lead revision 27 88,918 24 69,840 0.21
LV lead revision 5 16,466 15 43,650 0.02
Total episodes/cost 191 672,474 225 842,484 <0.001
Some patients were hospitalized for the same category more than once, and some
not at all. The cost of events was calculated by multiplying the number of events
in each year by the cost of the event for that year (i.e., events beyond year 1 were
multiplied by the discounted cost for the year in which the event occurred). aBased
on the tariff codes in Table 1.
ACS ¼ acute coronary syndrome; LV ¼ left ventricular; RA ¼ right atrial; RV ¼
right ventricular.
TABLE 4 Numbers a
Hospitalized Once (or
ACS
Arrhythmia
Heart failure
System explantation an
reimplantation
Generator replacement
Lead revision (RA/RV/L
Hospitalization (any ca
Values are n (%).
CI ¼ conﬁdence interval
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6lead revisions were similar between the groups (p ¼
NS). Each hospitalization, irrespective of cause, was
counted as a separate event (Table 3); these values
were multiplied by the appropriate tariff (Table 1) to
produce health-care utilization costs for each group
over the 5-year period.
Table 4 represents the proportion of patients
implanted with either quadripolar or bipolar leads
who had at least 1 admission for the listed reasons.
The absolute values for the hospitalization causes are
therefore less than in Table 3, because each of the
events are only counted once per patient. The pro-
portions of patients hospitalized at least once for
heart failure (8.8% [quadripolar] vs. 13.9% [bipolar];
p ¼ 0.05) or generator replacement (2.5% [quad-
ripolar] vs. 6.6% [bipolar]; p ¼ 0.02) were signiﬁ-
cantly lower in those in whom a quadripolar lead was
implanted. The average number of admissions fornd Proportions of Patients in Each Group Who Have Been
More)
Quadripolar
(n ¼ 319)
Bipolar
(n ¼ 287) Odds Ratio (95% CI) p Value
26 (8.2%) 17 (5.9%) 1.40 (0.75–2.66) 0.34
39 (12.2%) 45 (15.7%) 0.75 (0.47–1.19) 0.24
28 (8.8%) 40 (13.9%) 0.59 (0.36–0.99) 0.05
d 5 (1.6%) 6 (2.1%) 0.75 (0.23–2.47) 0.83
8 (2.5%) 19 (6.6%) 0.36 (0.15–0.84) 0.02
V) 30 (9.4%) 32 (11.2%) 0.83 (0.49–1.40) 0.50
use) 136 (42.6%) 159 (55.4%) 0.59 (0.43–0.83) 0.002
; other abbreviations as in Table 3.those who were hospitalized was similar in each
group (1.40 vs. 1.42, quadripolar vs. bipolar).
COST-EFFECTIVENESS ANALYSIS. The base-case
ICER was £3,692 ($5,538) in the deterministic model
(i.e., based on point estimates) and £3,835 ($5,753) in
the probabilistic model. Up to an additional purchase
cost of £932 ($1,398), quadripolar leads translated into
a cumulative cost saving compared with bipolar leads
because of the higher health-care utilization costs
associated with the latter (Figure 3). The cost saving
was up to £1,000 ($1,500) for purchasing a quadripolar
system for the same price as a bipolar system
(Table 5). Beyond £932 ($1,398), the additional ICER
was up to £20,288 ($30,432) (Figure 3). Figure 2 shows
the impact of varying a range of input parameters by
 95% conﬁdence intervals. The analysis was most
sensitive to the utility of patients with heart failure,
because death resulted in a loss of 0.8808 QALYs in
each patient who died. All resulting ICERs remained
less than £4,000 per QALY gained.
In the probabilistic sensitivity analysis, quad-
ripolar CRTD was 97.1% likely to be cost-effective at
£20,000 per QALY gained and 99.3% likely to be cost-
effective at £30,000 per QALY gained (Figure 4). A
cost-effectiveness panel showing the results of each
of the 1,000 simulations provides a visualization of
the proportion of cases for which quadripolar systems
were more effective and more expensive and for
which they were more effective and less expensive
(Figure 5).
DISCUSSION
This is the ﬁrst comprehensive health economic anal-
ysis to use real-world UK clinical data from hospitali-
zation events and mortality to produce an accurate
comparison of cumulative cost differences between
implanting quadripolar versus bipolar CRTD systems.
The main ﬁndings were as follows:
1. There was a lower absolute number of hospitali-
zations in patients in whom quadripolar CRTD
systems were implanted, predominantly driven by
a reduction in readmissions for heart failure and
generator replacements.
2. Quadripolar CRTD systems, if purchased for up to
£932 ($1,398) more than bipolar systems, yielded a
cost saving over a 5-year period after health-care
utilization costs were considered.
3. Quadripolar CRTD systems with an additional
purchase price of £933 to £2,400 ($1,400 to $3,600)
compared with bipolar systems remained cost-
effective, with ICER values well within the range
of acceptability used by NICE.
FIGURE 3 Incremental Cost and Cost-Effectiveness of Implanting a Quadripolar Versus Bipolar CRT-D System, Varied by the Additional
Acquisition Cost of the Quadripolar System
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Quadripolar (quad) leads that cost up to £932 ($1,398) more than bipolar leads result in either a cost-neutral outcome or a cost saving
because of reduced health-care utilization events. CRT-D ¼ cardiac resynchronization deﬁbrillator therapy device; ICER ¼ incremental
cost-effectiveness ratio.
TABLE 5 Cumulative Total Cost of Implanting a Quadripolar
Versus Bipolar CRTD for Different Acquisition Prices and
Associated ICERs
Additional Acquisition
Cost of Quadripolar
CRTD (£)
5-Yr Incremental
Cost of Quadripolar
vs. Bipolar CRTD (£)
ICER of Quadripolar
vs. Bipolar CRTD
0 1,000 Quadripolar dominates
200 786 Quadripolar dominates
400 571 Quadripolar dominates
600 357 Quadripolar dominates
800 143 Quadripolar dominates
1,000 72 £926
1,200 286 £3,692
1,400 501 £6,458
1,600 715 £9,224
1,800 929 £11,990
2,000 1,144 £14,756
2,200 1,358 £17,522
2,400 1,572 £20,288
CRTD ¼ cardiac resynchronization deﬁbrillator therapy device; ICER ¼ incremental
cost-effectiveness ratio; Quadripolar dominates ¼ quadripolar CRTD is less costly
and more effective than bipolar CRTD at 5 years. In this situation, ICERs are
negative and not conventionally shown.
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74. The calculated cost-effectiveness using real-world
clinical data (deterministic model) was closely
mirrored by the probabilistic sensitivity analysis,
which reafﬁrms conﬁdence in the results.
Multipolar LV leads for CRT delivery have
demonstrated high implant success, good capture
thresholds at implantation and follow-up, and a low
rate of lead displacement (11,26). Rates of intra-
procedural lead complications appear lower than with
conventional bipolar leads (27). Reduction or even
elimination in PNS during medium-term follow-up
provides invaluable utility in CRT delivery (9,15). We
have recently shown a reduction in all-cause mortal-
ity associated with quadripolar leads compared with a
bipolar lead (17). Furthermore, rates of reintervention
for lead repositioning were lower in those implanted
with a quadripolar compared with a bipolar lead (2%
vs. 5.2%, p ¼ 0.03), and the radiation dose during
implantation was almost half (1,028 cGy$cm2 vs. 1,950
cGy$cm2; p < 0.001).
The lower rates of hospitalization associated with
a quadripolar lead in the current study could be
driven by the improved efﬁcacy in CRT delivery
(attributable to PNS reduction and fewer reinter-
ventions for lead displacement). Our previous study
(17) also demonstrated lower implantation capture
energy with quadripolar than with bipolar leads(0.95 mJ vs. 1.08 mJ; p ¼ 0.003). Pacing systems
consistently delivering higher-output voltages to
capture the LV will have a reduced longevity (28),
and this could explain the current ﬁndings of a
FIGURE 4 Cost-Effectiveness Acceptability Curve for Quadripolar Versus Bipolar
CRTD
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The x-axis shows the willingness-to-pay threshold (i.e., the incremental cost per QALY
gained). Quadripolar (Quad) CRTD is 97.1% likely to be cost-effective at £20,000
($30,000) per QALY gained and 99.3% likely to be cost-effective at £30,000 ($45,000)
per QALY gained. Abbreviations as in Figure 2.
FIGURE 5 Cost-Eff
Each point represent
vertical axis are simu
expensive than bipol
in which quadripolar
diagonal black line is
this are simulation re
£20,000 [$30,000]
Behar et al. J A C C : C L I N I C A L E L E C T R O P H Y S I O L O G Y V O L . - , N O . - , 2 0 1 6
Cost-Effectiveness of Quadripolar vs. Bipolar CRTD - , 2 0 1 6 :- –-
8signiﬁcantly lower number of generator re-
placements among those implanted with a quad-
ripolar system. This might be of signiﬁcant clinical
importance given the higher prevalence of device-
related infections after generator replacement (29),
which might contribute to greater morbidity andectiveness Plane
s the result of 1 of the 1,000 simulations. Points to the left of the
lation results in which quadripolar CRTD was more effective and less
ar CRTD. Points to the right of the vertical axis are simulation results
CRTD was more effective and more expensive than bipolar CRTD. The
the £20,000 ($30,000) per QALY gained line (i.e., all points above
sults in which the incremental cost per QALY gained was less than
). Abbreviations as in Figure 2.mortality in this group. Furthermore, from an eco-
nomic modeling perspective, the lower proportion
of generator changes in the quadripolar group was
contributory to the lower overall health-care utili-
zation costs over the follow-up period. The pres-
ence of 4 poles on the quadripolar LV lead allows
greater programmability and the ability to choose
multiple vectors for CRT delivery (30,31). This pro-
vides the implanting physician with more choices
for implantation locations, which might allow leads
to be implanted more distally in posterolateral or
lateral veins for stability purposes (8,17), with the
ability to stimulate the LV more basally from the
proximal poles, which in turn could contribute to
more optimal CRT delivery and could result in
fewer heart failure hospitalizations and reduced
mortality.
COMPARISON WITH PREVIOUS STUDIES. Forleo
et al. (32) have reported reduced rates of heart
failure hospitalizations and LV lead revision among
patients implanted with a quadripolar lead in a
single-center Italian registry (events per patient per
year: 0.15 vs. 0.32, quadripolar vs. bipolar; p ¼
0.04). Non–heart failure hospitalization rates were
similar among groups. This study demonstrated
lower health-care utilization costs associated with
the quadripolar group (434 euros/patient-year vs.
1136 euros/patient-year; p ¼ 0.02). However, the
study by Forleo et al. (32) used Italian cost data that
cannot be directly translated into the UK health-
care setting, used only single-center data, had a
much shorter follow-up period, included a smaller
number of patients (193 vs. 606), and did not
include as wide a range of clinical events in the
follow-up costing. In the present study, the time to
each event was calculated individually from the
time of original implantation. In addition, the pre-
sent study recorded and coded for all relevant acute
and elective hospitalizations, not just heart failure
and LV lead revisions, including admissions with
ACS, arrhythmia, generator replacements, device
extractions/reimplantation, and all right atrial and
right ventricular lead revisions. Our calculated cu-
mulative 5-year cost analysis was paralleled by the
5-year follow-up data, which provides conﬁdence in
the clinical relevance and accuracy of this study.
Furthermore, we undertook a probabilistic sensi-
tivity analysis similar to that by Forleo et al. (32),
and the results for the base-case ICER closely
mirrored the value calculated in the deterministic
model. The only other contemporary UK-speciﬁc
cost-effectiveness analysis was published recently
by NICE (33). Recommendations made by NICE in a
2014 review of CRT and implantable deﬁbrillators
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Quadripolar
leads are associated with a lower rate of hospitalization than
bipolar leads, primarily driven by fewer heart failure read-
missions and generator replacements. This translates into a
lower health-care utilization cost over a 5-year follow-up
period and offsets the additional purchase price of quadri-
polar CRTD systems, which makes this technology highly
cost-effective.
TRANSLATIONAL OUTLOOK: Given the near elimination of
PNS, the reduction in hospital readmissions for generator
replacement and heart failure, and the observed lower mortality
in patients implanted with quadripolar leads, quadripolar CRTD
systems may be considered the standard of care for CRT
delivery.
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9for heart failure were based on plausible ICERs in
the range of £11,000 ($16,500) to £31,000 ($46,500)
per QALY gained (19). By way of comparison, our
results showed ICERs for quadripolar systems of up
to £20,288 ($30,432) per QALY gained. Had data
been available to include QALY adjustments for
arrhythmia admissions, device removal and reim-
plantation for wound infection, generator changes,
and lead revisions, it is likely that the ICERs would
have been lower, because the rates of these events
favor the quadripolar system. This analysis is
therefore conservative with respect to the cost-
effectiveness of quadripolar CRTD.
STUDY LIMITATIONS. The data used as the basis of
this economic evaluation were derived from a multi-
center clinical registry, and the choice of whether
quadripolar or bipolar leads were implanted was not
subject to a randomization process. However, the
approach we have taken reﬂects current demands in
which real-world data are becoming more important
to assess the impact that new technologies have
actually had on patients and health systems. We took
real clinical events that occurred in NHS practice and
applied NHS tariffs to them to determine the actual
charge and cost-effectiveness. This was an in-study
cost-effectiveness analysis, not an extrapolation to a
lifetime horizon. We therefore did not assume event
rates and did not model beyond the time for which we
had gathered follow-up data. We did not perform a
Markov model. Wider societal beneﬁt was also not
taken into account, which might be a further
limitation.
As might be expected, the incremental acquisi-
tion cost of quadripolar technology is a strong
determinant of the overall incremental cost-
effectiveness of the 2 therapies. We therefore
made an estimate of base cost and performed an
analysis either side of the additional purchase cost
to account for the variation in procurement acqui-
sition costs. With respect to QALYs, the mortality
difference was the strongest driver of the QALY gainassociated with quadripolar CRTD. There was a
signiﬁcant difference in the proportions of patients
with ischemic heart disease and those not in sinus
rhythm (with more such patients in the bipolar
group); however, this was corrected for in the
multivariate analysis, and mortality remained
signiﬁcantly different.
CONCLUSIONS
In a 5-year time horizon calculated from a UK health-
care system perspective, the additional purchase
price of quadripolar CRTD systems is substantially
offset by lower health-care utilization costs, which
suggests this technology is highly cost-effective
compared with bipolar systems.
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